S. Sledai, . Bilag, S. Eclam, . Sledai, and . Slam-r-2, Néphropathie active, définie par les analyses d'urine, la clairance à la créatinine, la protéinurie 3. Les poussées d'exacerbation de la maladie II, Atteintes des organes 1. Index A.C.R./SLICC 2. I.R. stade terminal 3. Taux de créatinine sérique doublé, p.36

A. Rahman and D. A. Isenberg, Systemic Lupus Erythematosus, New England Journal of Medicine, vol.358, issue.9, pp.929-939, 2008.
DOI : 10.1056/NEJMra071297

M. Olivier, Lupus systémique chez les non-Caucasiens, Revue du Rhumatisme Vol, vol.698, pp.801-808, 2002.

. Stoermann-chopard, Nephropathie membraneuse de type lupique: étude morphologique de 7

. Meyer, Crit??res de classification??: mode d'emploi pour le diagnostic de lupus syst??mique, Revue du Rhumatisme, vol.72, issue.2
DOI : 10.1016/j.rhum.2004.12.001

E. M. Tan, A. S. Cohen, J. F. Fries, A. T. Masi, D. J. Mcshane et al., The 1982 revised criteria for the classification of systemic lupus erythematosus, Arthritis & Rheumatism, vol.31, issue.11, pp.1271-1277, 1982.
DOI : 10.1002/art.1780220817

. Hughes and . Lupus, pdf (page consulté en juillet 2008) 10. Hannedouche. Lupus Généralités, N Engl J Med Feb, vol.28358, issue.9, pp.929-968, 2000.

E. M. Tan and H. G. Kunkel, Characteristics of a soluble nuclear antigen precipitating with sera of patients with systemic lupus erythematosus The role of APRIL and BAFF in lymphocyte activation, J. Immunol. J Immunol Feb Curr Opin Immunol, vol.9617617, issue.133, pp.464-4711297, 1966.

J. Morel, J. Gottemberg, J. Sibilia, and C. B. , Le Lymphocyte B : cible privilégiée des maladies auto-immunes, Magazine Article] 15. L. Weiss, F. Maillet, and M. Kazatchkine. Lupus and protein deficiencies of the classical complement pathway, pp.745-7501937, 1990.
DOI : 10.1016/j.rhum.2007.05.006

J. Chikirate, . Rouichi, . Bentahila, and A. Belhadj, Les Déficits en protéines du complement en pathologie, 1999.

. Licciardi, The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial, Ann Intern Med, vol.142, pp.953-962, 2005.

. Le-lupus-Érythémateux-disséminé, Généralités et symptomes [Magazine Article] 22. Hannedouche. Néphropathies lupiques, 2007.

C. Kong, P. Lesavre, M. Lockshin, L. M. Looi, H. Makino et al., The classification of glomerulonephritis in systemic lupus erythematosus revisited, Kidney Int, vol.65, pp.521-530, 2004.

R. S. Flanc, M. A. Roberts, G. F. Strippoli, S. J. Chadban, P. G. Kerr et al., Treatment for lupus nephritis, Cochrane Database Syst Rev, p.2922, 2004.

. Hannedouche, Traitement des Néphropathies lupiques, 2007.

S. Française-de-dialyse, [Internet Communication] URL: www.sfdial.org (page consulté en janvier 2009) 31. F. A. Houssiau. Traitement de la néphropathie lupique, Actualités néphrologiques, pp.133-144, 2005.

. Danieli, Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial, Arthritis Rheum, vol.50, pp.3934-3940, 2004.

F. A. Houssiau, C. Vasconcelos, D. D-'cruz, G. D. Sebastiani, G. E. De-ramon et al., The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide, Annals of the Rheumatic Diseases, vol.69, issue.01, pp.61-64, 2010.
DOI : 10.1136/ard.2008.102533

J. Karsh, R. P. Kimberly, N. I. Stahl, P. H. Plotz, J. L. Decker et al., Comparative effects of aspirin and ibuprofen in the management of systemic lupus erythematosus Letter: Ibuprofen for systemic lupus erythematosus, 779. 37. I. M. Meinao, E. I. Sato, L. E. Andrade, M. B. Ferraz, and E. Atra. Controlled trial with chloroquine diphosphate in systemic lupus erythematosus, pp.237-278, 1975.

E. L. Bezerra, M. J. Vilar, P. B. Da-trindade, E. I. Neto, and . Sato, Double-blind, randomized, controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosus, Arthritis & Rheumatism, vol.5, issue.10, pp.3073-3081, 2005.
DOI : 10.1002/art.21358

C. G. Kworth-young, J. David, S. H. Morgan, and G. R. Hughes, A double blind, placebo controlled trial of intravenous methylprednisolone in systemic lupus erythematosus Corticosteroids and neuropsychological functioning in patients with systemic lupus erythematosus, Ann Rheum Dis Arthritis Rheum, vol.4737, issue.69, pp.496-5021311, 1988.

K. Rosenthal, V. Haines, S. B. Ilie, and . Abramson, The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial, 43. Zouali M. Molecular autoimmunity, 2005. 44. Sibilia and Sordet. Immunothérapies du lupus systémique: innovations et perspectives, pp.3623-32572, 2005.

J. Sibilia, J. E. Gottenberg, X. Mariette, R. J. Looney, J. H. Anolik et al., Rituximab: A new therapeutic alternative in rheumatoid arthritis, Joint Bone Spine, vol.75, issue.5, pp.526-322580, 2004.
DOI : 10.1016/j.jbspin.2008.02.009

M. J. Leandro, J. C. Edwards, G. Cambridge, M. R. Ehrenstein, and D. A. Isenberg, An open study of B lymphocyte depletion in systemic lupus erythematosus, Genentech. Phase III Study of Rituxan in Lupus Nephritis Did Not Meet Primary Endpoint, pp.2673-2680, 2002.
DOI : 10.1055/s-2001-17109

F. Fakhouri, H. Guerraoui, . Knebelmann, R. Salomon, P. Niaudet et al., Le rituximab dans les maladies auto-immunes : un nouvel espoir ? In Flammarion Recommandation d'utilisation du cyclophosphamide dans les maladies auto-immunes (Commission de la Transparence), Actualités néphrologiques Jean Hamburger: Hôpital Necker, 2004.

F. Lajaunias, A. Ida, S. Kikuchi, L. Fossati-jimack, E. Martinez-soria et al., Differential control of CD22 ligand expression on B and T lymphocytes, and enhanced expression in murine systemic lupus, Arthritis & Rheumatism, vol.98, issue.6, pp.1612-1633, 2003.
DOI : 10.1073/pnas.98.3.1142

J. M. Harper and A. Cook, Mice with Active Systemic Lupus Erythematosus and Microscopic Angiitis, Autoimmunity, vol.33, issue.4, pp.245-251, 2001.
DOI : 10.1080/08916934.2002.11873701

F. J. Stafford, T. A. Fleisher, G. Lee, M. Brown, V. Strand et al., A pilot study of anti-CD5 ricin A chain immunoconjugate in systemic lupus erythematosus, J Rheumatol, vol.21, pp.2068-2070, 1994.

D. M. Gitelman, D. Harlan, R. A. Xu, J. A. Zivin, and . Bluestone, Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus, N Engl J Med, vol.346, pp.1692-1698, 2002.

T. Higuchi, Y. Aiba, T. Nomura, J. Matsuda, K. Mochida et al., Cutting Edge: Ectopic Expression of CD40 Ligand on B Cells Induces Lupus-Like Autoimmune Disease, The Journal of Immunology, vol.168, issue.1, pp.9-12, 2002.
DOI : 10.4049/jimmunol.168.1.9

S. L. Kalled, A. H. Cutler, S. K. Datta, and D. W. Thomas, Anti-CD40 ligand antibody treatment of SNF1 mice with established nephritis: preservation of kidney function, J Immunol, vol.160, pp.2158-2165, 1998.

J. C. Davis, J. , M. C. Totoritis, J. Rosenberg, T. A. Sklenar et al., Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus, J Rheumatol, vol.28, pp.95-101, 2001.

K. C. Kalunian, J. C. Davis, J. , J. T. Merrill, M. C. Totoritis et al., Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: A randomized, double-blind, placebo-controlled trial, Arthritis & Rheumatism, vol.43, issue.12, pp.3251-3258, 2002.
DOI : 10.1038/72162

X. Wang, W. Huang, M. Mihara, J. Sinha, and A. Davidson, Mechanism of Action of Combined Short-Term CTLA4Ig and Anti-CD40 Ligand in Murine Systemic Lupus Erythematosus, The Journal of Immunology, vol.168, issue.4, pp.2046-2053, 2002.
DOI : 10.4049/jimmunol.168.4.2046

E. A. Greenfield, K. A. Nguyen, and V. K. Kuchroo, CD28/B7 Costimulation: A Review, Critical Reviews??? in Immunology, vol.18, issue.5, pp.389-418, 1998.
DOI : 10.1615/CritRevImmunol.v18.i5.10

P. Dougados, I. F. Emery, G. R. Nuamah, J. C. Williams, D. T. Becker et al., Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig, N Engl J Med, vol.349, pp.1907-1915, 2003.

D. I. Daikh and D. Wofsy, Cutting Edge: Reversal of Murine Lupus Nephritis with CTLA4Ig and Cyclophosphamide, The Journal of Immunology, vol.166, issue.5, pp.2913-2916, 2001.
DOI : 10.4049/jimmunol.166.5.2913

M. Takiguchi, M. Murakami, I. Nakagawa, I. Saito, A. Hashimoto et al., CTLA4IgG gene delivery prevents autoantibody production and lupus nephritis in MRL/lpr mice, Life Sciences, vol.66, issue.11, pp.991-1001, 2000.
DOI : 10.1016/S0024-3205(99)00664-5

N. Najafian and M. H. Sayegh, CTLA4-Ig: a novel immunosuppressive agent, Expert Opinion on Investigational Drugs, vol.159, issue.10, pp.2147-2157, 2000.
DOI : 10.1056/NEJM199906033402202

L. Llorente and Y. Richaud-patin, The role of interleukin-10 in systemic lupus erythematosus, Journal of Autoimmunity, vol.20, issue.4, pp.287-289, 2003.
DOI : 10.1016/S0896-8411(03)00043-X

J. Tyrrell-price, P. M. Lydyard, and D. A. Isenberg, The effect of interleukin-10 and of interleukin-12 on the in vitro production of anti-double-stranded DNA antibodies from patients with systemic lupus erythematosus, Clinical and Experimental Immunology, vol.183, issue.9, pp.118-125, 2001.
DOI : 10.1084/jem.183.6.2559

A. E. Mongan, S. Ramdahin, and R. J. Warrington, Interleukin-10 Response Abnormalities in Systemic Lupus Erythematosus, Scandinavian Journal of Immunology, vol.46, issue.4, pp.406-412, 1997.
DOI : 10.1046/j.1365-3083.1997.d01-140.x

. Craft, IL-10 regulates murine lupus, J Immunol, vol.169, pp.2148-2155, 2002.

T. Fujii, M. Okada, T. Mimori, and J. Craft, The transmembrane form of TNF-alpha drives autoantibody production in the absence of CD154: studies using MRL/Mp-Faslpr mice, Clinical and Experimental Immunology, vol.159, issue.2, pp.224-232, 2002.
DOI : 10.4049/jimmunol.165.7.4095

P. A. Yazici and . Guerne, Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity, J Rheumatol, vol.24, pp.303-308, 1997.

B. Fautrel, V. Foltz, C. Frances, P. Bourgeois, and S. Rozenberg, Regression of subacute cutaneous lupus erythematosus in a patient with rheumatoid arthritis treated with a biologic tumor necrosis factor ?-blocking agent: Comment on the article by Pisetsky and the letter from Aringer et al, Arthritis & Rheumatism, vol.108, issue.5, pp.1408-1409, 2002.
DOI : 10.1016/S0002-9343(99)00408-8

M. A. Gill, P. Blanco, E. Arce, V. Pascual, J. Banchereau et al., Blood dendritic cells and DC-poietins in systemic lupus erythematosus, Human Immunology, vol.63, issue.12, pp.1172-1180, 2002.
DOI : 10.1016/S0198-8859(02)00756-5

P. L. Gilburd, Y. Meroni, and . Shoenfeld, Immunomodulation of murine experimental SLE-like disease by interferon-gamma, Lupus, vol.7, pp.445-454, 1998.

C. Haas, B. Ryffel, and H. M. Le, IFN-gamma is essential for the development of autoimmune glomerulonephritis in MRL/Ipr mice, J Immunol, vol.158, pp.5484-5491, 1997.

P. Schneider, F. Mackay, V. Steiner, K. Hofmann, J. Bodmer et al., BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth, The Journal of Experimental Medicine, vol.85, issue.11, pp.1747-1756, 1999.
DOI : 10.1126/science.7537388

M. Hahne, T. Kataoka, M. Schröter, K. Hofmann, M. Irmler et al., APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth An APRIL to remember: novel TNF ligands as therapeutic targets, J Exp Med. Nat Rev Drug Discov, vol.188, issue.5, pp.1185-1190235, 1998.

P. Schneider, The role of APRIL and BAFF in lymphocyte activation, Current Opinion in Immunology, vol.17, issue.3, pp.1-8, 2005.
DOI : 10.1016/j.coi.2005.04.005

F. Mackay, S. A. Woodcock, P. Lawton, C. Ambrose, M. Baetscher et al., Mice Transgenic for Baff Develop Lymphocytic Disorders along with Autoimmune Manifestations, The Journal of Experimental Medicine, vol.51, issue.11, pp.1697-1710, 1999.
DOI : 10.1038/32588

URL : http://jem.rupress.org/content/jem/190/11/1697.full.pdf

. Tschopp, BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth, J Exp Med, vol.189, pp.1747-1756, 1999.

K. O. Diamond, S. Yu, A. Porcelli, and . Davidson, Similarities and differences between selective and nonselective BAFF blockade in murine SLE, J Clin Invest, vol.116, pp.724-734, 2006.

D. Seshasayee, P. Valdez, M. Yan, V. M. Dixit, D. Tumas et al., Loss of TACI Causes Fatal Lymphoproliferation and Autoimmunity, Establishing TACI as an Inhibitory BLyS Receptor, Immunity, vol.18, issue.2, pp.279-288, 2003.
DOI : 10.1016/S1074-7613(03)00025-6

T. Kimberly and . Zhou, Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus, J Immunol, vol.166, pp.6-10, 2001.

. Horiuchi, Raised serum APRIL levels in patients with systemic lupus erythematosus, Ann Rheum Dis, vol.64, pp.1065-1067, 2005.

W. Stohl, S. Metyas, S. M. Tan, G. S. Cheema, B. Oamar et al., Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus, Annals of the Rheumatic Diseases, vol.63, issue.9, pp.1096-1103, 2004.
DOI : 10.1136/ard.2003.018663

W. Harrison, C. H. Kindsvogel, and . Clegg, TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease, Nature, vol.404, pp.995-999, 2000.

W. Harrison, C. H. Kindsvogel, and . Clegg, TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease, Nature, vol.404, pp.995-999, 2000.

M. Carbonatto, P. Yu, M. Bertolino, E. Vigna, S. Steidler et al., Nonclinical Safety, Pharmacokinetics, and Pharmacodynamics of Atacicept, Nonclinical safety, pharmacokinetics, and pharmacodynamics of atacicept, pp.200-210, 2008.
DOI : 10.1038/sj.leu.2405048

A. Madaio and . Davidson, Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus, J Immunol, vol.173, pp.3524-3534, 2004.

A. Munafo, A. Priestley, I. Nestorov, J. Visich, and M. Rogge, Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers, European Journal of Clinical Pharmacology, vol.166, issue.7, pp.647-656, 2007.
DOI : 10.4049/jimmunol.166.1.6

A. J. Novak, R. J. Bram, N. E. Kay, and D. F. Jelinek, Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival, Blood, vol.100, issue.8, pp.2973-2979, 2002.
DOI : 10.1182/blood-2002-02-0558

K. M. Harder, R. J. Ristow, D. F. Bram, J. A. Jelinek, and S. M. Gross, Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome, Blood, pp.2247-2253, 2004.

T. S. Ansell, D. J. Witzig, L. F. Inwards, and . Porrata, URL: www.e-cancer.fr (page consulté en septembre 2009) 98

S. R. Devries, D. Dillon, A. J. Hausman, and . Novak, Phase I clinical study of atacicept in patients with relapsed and refractory B-cell non-Hodgkin's lymphoma, Clin Cancer Res, Press Release: Atacicept in Leukemia. 2009. [Internet Communication, pp.1105-1110, 2008.

. Myélome-multiple, Internet Communication] URL: www.med.univ-rennes1.fr (page consulté en septembre, 2009.

S. Goldsmith, R. Kieszak, and . Lightfoot, The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials, Arthritis Rheum, vol.36, pp.729-740, 1993.

. Silman-a, M. Hochberg, .. G. Cheema, V. Roschke, D. M. Hilbert et al., Epidemiology of the rheumatic diseases Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases, Arthritis Rheum, vol.44, pp.1313-1319, 2001.

M. Hilbert and W. Stohl, Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis, Arthritis Rheum, vol.48, pp.982-992, 2003.

P. P. Tak, R. M. Thurlings, C. Rossier, I. Nestorov, A. Dimic et al., Atacicept in patients with rheumatoid arthritis: Results of a multicenter, phase ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study, Arthritis & Rheumatism, vol.38, issue.1, pp.61-72, 2008.
DOI : 10.4049/jimmunol.169.8.4314

I. Nestorov, A. Munafo, O. Papasouliotis, and J. Visich, Pharmacokinetics and Biological Activity of Atacicept in Patients With Rheumatoid Arthritis, The Journal of Clinical Pharmacology, vol.54, issue.4, pp.406-417, 2008.
DOI : 10.1002/art.21650

S. Baker, B. Ullrich, D. M. Nardelli, T. S. Hilbert, and . Migone, BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases, J Immunol, vol.169, pp.4314-4321, 2002.

P. Kalunian, E. Dhar, C. Vincent, D. Pena-rossi, and . Wofsy, Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial, Arthritis Rheum, pp.4142-4150, 2007.

J. Antel and A. Bar-or, Roles of immunoglobulins and B cells in multiple sclerosis: From pathogenesis to treatment, Journal of Neuroimmunology, vol.180, issue.1-2, pp.3-8, 2006.
DOI : 10.1016/j.jneuroim.2006.06.032

M. Cucherat, Petit Manuel de lecture critique des essais cliniques

M. Cucherat, M. Lièvre, A. Leizerovicz, and J. Boissel, Lecture critique et interprétation des résultats des essais cliniques pour la pratique médicale [Validation of surrogate endpoints in digestive oncology], Bull Cancer, pp.591-595, 2004.

. Affsaps, Choix de la première dose, de la progression de dose et protocole d'administration aux volontaires [Report] 115. EMEA. ICH E10 Choice of control group and related issues in clinicals trials Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects - Adopted by the 18th WMA General Assembly, 1964.

R. Ponce, Preclinical Support for Combination Therapy in the Treatment of Autoimmunity with Atacicept, Cucherat M. Lecture critique des essais thérapeutiques. [Internet Communication, pp.89-99437, 2006.
DOI : 10.1126/science.1086907

V. Strand, Lessons learned from clinical trials in SLE, Autoimmunity Reviews, vol.6, issue.4, pp.209-214, 2007.
DOI : 10.1016/j.autrev.2006.08.002

J. Schiffenbauer and L. S. Simon, Randomized controlled trials in systemic lupus erythematosus: what has been done and what do we need to do?, Lupus, vol.26, issue.5, pp.398-405, 2004.
DOI : 10.1002/art.10461

M. D. Bagin, B. Linnik, and . Hepburn, LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study, Arthritis Rheum, vol.48, pp.442-454, 2003.

T. M. Chan, F. K. Li, C. S. Tang, R. W. Wong, G. X. Fang et al., Efficacy of Mycophenolate Mofetil in Patients with Diffuse Proliferative Lupus Nephritis, New England Journal of Medicine, vol.343, issue.16, pp.1156-1162, 2000.
DOI : 10.1056/NEJM200010193431604

L. Gmelig-meyling, C. Kater, and . Kallenberg, Prevention of relapses in systemic lupus erythematosus, Lancet, vol.345, pp.1595-1599, 1995.

M. Corzillius and S. C. Bae, Methodological issues of corticosteroid use in SLE clinical trials, Lupus, vol.31, issue.8, pp.692-697, 1999.
DOI : 10.1016/0140-6736(90)90014-V

F. Fakhouri and P. Lesavre, Quel traitement pour les néphropathies lupiques en 2008? In Flammarion, Actualités néphrologiques, pp.217-227, 2008.

G. P. Release, URL: http://www.rheumatology.org (page consulté en Décembre, htm (page consulté en Janvier 2010) 133. ACR criteria. [Internet CommunicationRPS) 2003 Classification of Lupus Nephritis. [Internet Communication, 2009.